Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

TreeHouse Foods Faces Slowdown as Shoppers Cut Back on Even Cheaper Groceries

by Team Lumida
March 5, 2025
in Health and Longevity
Reading Time: 4 mins read
A A
0
high-angle photography of grocery display gondola

Photo by Peter Bond on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • TreeHouse Foods, a major supplier of private-label goods for retailers like Walmart and Target, is experiencing slower sales growth as inflation-weary consumers reduce spending on lower-cost groceries.
  • The company is focusing on cost-cutting measures, including supply-chain efficiencies and product adjustments, to protect margins in a challenging demand environment.
  • TreeHouse is expanding selectively through acquisitions while exiting less profitable product lines to streamline operations.
  • Analysts emphasize the need for operational improvements after recent production issues and recalls.

What Happened?

TreeHouse Foods, a leading manufacturer of private-label products for major retailers, is seeing a slowdown in sales growth as inflation-strained consumers cut back on even lower-cost grocery items. While private-label goods gained popularity during the pandemic and inflationary periods, demand has softened recently, with unit sales in key categories growing just 0.6% in late 2024 compared to 4.5% growth earlier in the year. In response, TreeHouse is implementing cost-saving measures, such as automating production processes and renegotiating supplier contracts, to reduce supply-chain costs by $250 million by 2027. The company is also refining its product portfolio, exiting less profitable areas like ready-to-drink beverages while expanding in others, including coffee and tea, through strategic acquisitions.


Why It Matters?

The slowdown in private-label sales reflects broader consumer behavior shifts as inflation continues to pressure household budgets. For investors, this signals potential headwinds for companies reliant on discretionary spending, even in traditionally resilient sectors like groceries. TreeHouse’s focus on cost control and profitability over aggressive sales growth highlights the challenges of navigating a softer demand environment. Additionally, operational missteps, such as production delays and product recalls, have weighed on the company’s performance, underscoring the importance of execution in maintaining investor confidence.


What’s Next?

TreeHouse plans to continue its cost-cutting initiatives while selectively expanding into high-growth areas like coffee and tea. The company’s ability to streamline operations and avoid further production issues will be critical to stabilizing its performance. Analysts expect slower growth in the near term, with TreeHouse forecasting a 3.5% decline in adjusted net sales for the first quarter of 2025. Investors should monitor the company’s progress in improving operational efficiency, managing its product portfolio, and adapting to evolving consumer spending patterns.

Source
Previous Post

China Strikes Back: Tariffs and Export Controls Escalate U.S.-China Trade War

Next Post

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

Recommended For You

Sleep Is the Most Underrated Longevity Investment

by Team Lumida
1 hour ago
Sleep Paralysis Explained: The Science Behind Your Nightmares

Key takeaways Powered by lumidawealth.com Poor sleep is linked to higher risk of heart disease, diabetes, obesity, depression, and early mortality. Consistent sleep timing matters as much as total...

Read more

U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge

by Team Lumida
1 day ago
U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge

Key takeaways Powered by lumidawealth.com U.S. life expectancy rose to 79 years in 2024, the highest on record, up 0.6 years YoY Drug-overdose deaths fell more than 26%, the...

Read more

Longevity Hacks Go Data-Driven as Preventive Health Becomes a Scalable Growth Market

by Team Lumida
2 days ago
man running on road near grass field

Key takeaways Powered by lumidawealth.com Longevity is shifting from wellness trends to measurable, science-backed health optimization Simple behaviors like strength training, protein intake, sleep consistency, and fasting windows show...

Read more

Preventive Health and Aging Tech Emerge as the Next Major Growth Market

by Team Lumida
3 days ago
black and red cherries on white bowl

Key takeaways Powered by lumidawealth.com Longevity is moving from niche wellness to a core healthcare and investment theme, powered by aging demographics and tech-driven prevention Breakthroughs in early diagnostics,...

Read more

Cancer Survivors Face Growing Risk of Heart Damage from Life-Saving Treatments

by Team Lumida
1 week ago
Cancer Survivors Face Growing Risk of Heart Damage from Life-Saving Treatments

Key Takeaways Powered by lumidawealth.com Advances in cancer treatments are leading to more survivors, but many face delayed heart damage from therapies. Modern treatments like immune checkpoint inhibitors and...

Read more

Sleep Regularity Is the Longevity Edge Most People Ignore

by Team Lumida
1 week ago
woman sleeping on bed under blankets

Key takeaways Powered by lumidawealth.com Sleep regularity (same bedtime/wake time) often matters as much as total hours for metabolic and cardiovascular health. Big swings in sleep timing can impair...

Read more

Longevity Moves From Lifestyle Trend to Investable Theme as Aging Demographics Drive Demand

by Team Lumida
1 week ago
diagram

Key takeaways Powered by lumidawealth.com Aging demographics are accelerating demand for therapies and services that extend healthspan, not just lifespan. Capital is shifting from reactive care to prevention, chronic-disease...

Read more

Metformin: The “Longevity Drug” With Big Promise—and Unfinished Proof

by Team Lumida
1 week ago
Metformin: The “Longevity Drug” With Big Promise—and Unfinished Proof

Key takeaways Powered by lumidawealth.com Metformin is a low-cost, widely prescribed diabetes drug being studied for whether it can delay age-related disease beyond glucose control. The core debate: strong...

Read more

Rapamycin: The “Most-Proven-in-Mice” Longevity Drug Still Searching for Human Proof

by Team Lumida
2 weeks ago
Rapamycin: The “Most-Proven-in-Mice” Longevity Drug Still Searching for Human Proof

Key takeaways Powered by lumidawealth.com Rapamycin (sirolimus) has some of the strongest preclinical longevity evidence, but human data is still early and fragmented. The core investment challenge is translation...

Read more

GLP-1s Are Becoming the First “Longevity Drug” With Real-World Outcomes Data

by Team Lumida
2 weeks ago
GLP-1s Are Becoming the First “Longevity Drug” With Real-World Outcomes Data

Key takeaways Powered by lumidawealth.com GLP-1 drugs are shifting from “weight-loss meds” to risk-reduction platforms, with evidence supporting meaningful improvements in cardiometabolic outcomes in obese/overweight populations. The investable story...

Read more
Next Post
blue UTP cord

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

gold and black metal tool

Gold Surges as Trade War Escalation Drives Demand for Safe-Haven Assets

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

water dew on silver Volkswagen car emblem

Volkswagen Misses Q1 Earnings Expectations Amid Early Impact of U.S. Auto Tariffs

April 10, 2025
U.S. and Japan Strike Trade Deal, Lowering Tariffs and Securing Major Investment

U.S. and Japan Strike Trade Deal, Lowering Tariffs and Securing Major Investment

July 23, 2025
Alibaba Stumbles: Profit and Revenue Fall Short Despite Strong Growth Efforts

Alibaba Accelerates Core Business Pivot with $1.7B Sun Art Stake Sale

January 2, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018